These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy. Chen K, Cheng G, Zhang F, Zhu G, Xu Y, Yu X, Huang Z, Fan Y. Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230 [Abstract] [Full Text] [Related]
9. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. Althammer S, Tan TH, Spitzmüller A, Rognoni L, Wiestler T, Herz T, Widmaier M, Rebelatto MC, Kaplon H, Damotte D, Alifano M, Hammond SA, Dieu-Nosjean MC, Ranade K, Schmidt G, Higgs BW, Steele KE. J Immunother Cancer; 2019 May 06; 7(1):121. PubMed ID: 31060602 [Abstract] [Full Text] [Related]
10. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes. Chen L, Cao MF, Zhang X, Dang WQ, Xiao JF, Liu Q, Tan YH, Tan YY, Xu YY, Xu SL, Yao XH, Cui YH, Zhang X, Bian XW. Cancer Med; 2019 Dec 06; 8(17):7207-7218. PubMed ID: 31605439 [Abstract] [Full Text] [Related]
12. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L, Zhou C, Hirsch FR. J Thorac Oncol; 2017 May 06; 12(5):814-823. PubMed ID: 28132868 [Abstract] [Full Text] [Related]
14. Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy. Choe EA, Cha YJ, Kim JH, Pyo KH, Hong MH, Park SY, Shim HS, Jung I, Lee CY, Cho BC, Kim HR. Lung Cancer; 2019 Oct 06; 136():30-36. PubMed ID: 31421259 [Abstract] [Full Text] [Related]
17. Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. Mandarano M, Bellezza G, Belladonna ML, Van den Eynde BJ, Chiari R, Vannucci J, Mondanelli G, Ludovini V, Ferri I, Bianconi F, Del Sordo R, Cagini L, Albini E, Metro G, Puma F, Sidoni A. Virchows Arch; 2019 Feb 06; 474(2):159-168. PubMed ID: 30448912 [Abstract] [Full Text] [Related]
18. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer. Handa Y, Tsutani Y, Shiroma N, Kai Y, Mimae T, Miyata Y, Takeshima Y, Arihiro K, Okada M. Clin Lung Cancer; 2020 Jul 06; 21(4):e302-e314. PubMed ID: 32102750 [Abstract] [Full Text] [Related]
19. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. Morihiro T, Kuroda S, Kanaya N, Kakiuchi Y, Kubota T, Aoyama K, Tanaka T, Kikuchi S, Nagasaka T, Nishizaki M, Kagawa S, Tazawa H, Fujiwara T. Sci Rep; 2019 Mar 15; 9(1):4633. PubMed ID: 30874607 [Abstract] [Full Text] [Related]